Want to see HK:1276 full AI Analyst Report?
1276 Stock Chart & Stats
HK$46.50
HK$0.40(0.71%)
At close: 4:00 PM EDT
HK$46.50
HK$0.40(0.71%)
Day’s Range― - ―
52-Week RangeHK$43.02 - HK$80.95
Previous CloseN/A
Volume2.78M
Average Volume (3M)4.19M
Market Cap
HK$362.74B
Enterprise ValueHK$338.39B
Total Cash (Recent Filing)HK$44.89B
Total Debt (Recent Filing)HK$836.30M
Price to Earnings (P/E)39.8
Beta0.47
Next Earnings
Oct 27, 2026EPS Estimate
0.39Next Dividend Ex-DateN/A
Dividend Yield0.48%
Share Statistics
EPS (TTM)1.32
Shares Outstanding258,197,600
10 Day Avg. Volume4,729,267
30 Day Avg. Volume4,192,174
Financial Highlights & Ratios
PEG Ratio2.21
Price to Book (P/B)6.79
Price to Sales (P/S)13.15
P/FCF Ratio50.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$80.14Price Target Upside72.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1.61
Revenue Forecast (FY)HK$39.24B
Bulls Say, Bears Say
Bulls Say
High ProfitabilityVery high gross and net margins indicate strong economics across the company’s pharmaceutical portfolio and provide substantial capacity to fund research, clinical development, commercialization, and other strategic investments. Margin expansion since 2021 further supports the durability of its earnings profile.
Conservative Balance SheetMinimal debt relative to equity materially reduces solvency and refinancing risk, giving the company flexibility to sustain research spending, pursue growth opportunities, and absorb operating volatility. This conservative funding structure is a durable advantage in a capital-intensive pharmaceutical industry.
Strong Operating Cash FlowOperating cash flow exceeding reported earnings suggests that profits are converting into cash effectively, supporting confidence in earnings quality. Strong internal cash generation can help finance ongoing development and commercialization while reducing reliance on external funding despite recent free-cash-flow volatility.
Bears Say
Recent Revenue SoftnessRecent top-line softness indicates that strong margins have not been matched by consistent revenue expansion. If this pattern persists, it could limit operating leverage, reduce the scale benefits of the commercial platform, and constrain the pace at which earnings growth compounds over the next several quarters.
Volatile Free Cash FlowThe decline and volatility in free cash flow show that accounting profitability is currently translating into cash less fully than operating earnings. Higher reinvestment or working-capital requirements may therefore reduce near-term funding flexibility and make cash generation less predictable.
Moderate Equity ReturnsAlthough shareholder returns are healthy and consistent, the lack of recent acceleration suggests that capital is not producing increasingly stronger returns. This may limit the benefit of the company’s high margins unless future growth, operating efficiency, or capital deployment improves the return profile.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H News
1276 FAQ
What was Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s price range in the past 12 months?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H lowest stock price was HK$43.02 and its highest was HK$80.95 in the past 12 months.
What is Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s market cap?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s market cap is HK$362.74B.
When is Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s upcoming earnings report date?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s upcoming earnings report date is Oct 27, 2026 which is in 3 days.
How were Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s earnings last quarter?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H released its earnings results on Aug 19, 2026. The company reported HK$0.394 earnings per share for the quarter, missing the consensus estimate of HK$0.483 by -HK$0.089.
Is Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H overvalued?
According to Wall Street analysts Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s price is currently Undervalued.
Does Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H pay dividends?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H pays a Annually dividend of HK$0.228 which represents an annual dividend yield of 0.48%. See more information on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H dividends here
What is Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s EPS estimate?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s EPS estimate is 0.39.
How many shares outstanding does Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H have?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H has 258,197,600 shares outstanding.
What happened to Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s price movement after its last earnings report?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H reported an EPS of HK$0.394 in its last earnings report, missing expectations of HK$0.483. Following the earnings report the stock price went up 1.29%.
Which hedge fund is a major shareholder of Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:1276
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.18%
12-Months-Change
Fundamentals
Return on Equity
12.42%
Trailing 12-Months
Asset Growth
18.71%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276) Earnings & Revenues
1276 Stock 12 Month Forecast
Average Price Target
HK$80.14
▲(72.34% Upside)
Technical Analysis
Sino Biopharmaceutical
―
Innovent Biologics
―
Akeso, Inc.
―
Hansoh Pharmaceutical Group Company Limited
―
BeOne Medicines Ltd
―